SYK Stock Analysis — Stryker Corporation
Sector: Healthcare
AI Verdict
Stryker trades at 21.8x next year's earnings with sector-beating growth expectations, so this is cheap for the growth you're getting if its entrenched hospital relationships keep driving adoption.
Competitive Moat
Stryker manufactures orthopedic implants, surgical equipment, and hospital devices with a defensible moat from its deep integration into hospital procurement systems and long-term surgeon training programs. Its installed base and proprietary product lines create high switching costs for hospitals and clinicians.
Summary
Stryker is notable right now for a sharp expected earnings rebound, with analysts projecting 61.3% EPS growth over the next year.
Where It Stands
Stryker is down -11.18% over the past year, trades at 21.8x next year's earnings (below the 22x healthcare median), and its RSI of 45.0 signals cooling momentum.
Key Metrics
- RSI: 45 — Neutral
- Trailing P/E: 35.1x
- Forward P/E: 21.8x
- PEG Ratio: 0.57
- Earnings Growth: +0.6%
- Revenue Growth: +0.1%
- Market Cap: $130.1B
- Dividend Yield: 0.01%
- 1-Year Return: -11.18%
- 52-Week High: $396.86
- 52-Week Low: $281.00
Analyst Consensus
28 Buy · 6 Hold · 0 Sell (34 analysts)
Bull Case
With forward EPS growth expected at 61.3% and a forward P/E of 21.8x, you're paying a low price for unusually high growth in the sector.
Bear Case
If Stryker's forward P/E rerates back to its trailing 35.1x multiple, the stock would need a major rally to justify the current valuation, but if growth stalls, a drop to the sector's 22x median could mean further downside.
Catalyst to Watch
Watch for quarterly earnings to confirm the 61.3% EPS growth forecast—any miss could quickly erase the current valuation premium.